• Je něco špatně v tomto záznamu ?

A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study

D. Gruber, A. Skřivánek, M. Serrani, V. Lanius, M. Merz,

. 2015 ; 91 (2) : 105-12. [pub] 20141013

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16021028

OBJECTIVE(S): To investigate the bleeding pattern and cycle control parameters of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD) compared with a patch containing 0.6 mg EE and 6 mg norelgestromin (NGMN). STUDY DESIGN: In this phase III, open-label, randomized, parallel-group trial, healthy women aged 18-35 years (smokers aged 18-30 years) received either the EE/GSD patch (n=200) or the EE/NGMN patch (n=198). Treatment consisted of one patch per week for 3 weeks followed by a 7-day, patch-free interval for seven cycles. Bleeding control was assessed in two 90-day reference periods. RESULTS: In reference period 1, mean number of bleeding/spotting days was comparable across treatment groups (p>0.05). However, in reference period 2, there were fewer bleeding/spotting days in the EE/GSD patch group (15.7 versus 18.4; p<0.0001). Mean number of bleeding/spotting episodes was comparable across groups for both reference periods, but bleeding/spotting episodes were shorter for the EE/GSD patch than the EE/NGMN patch during reference period 1 (5.13 days versus 5.53 days, respectively; p<0.05) and reference period 2 (5.07 versus 5.66; p=0.0001). Both treatment groups showed a similar frequency of withdrawal bleeding episodes; however, across all seven cycles, the length of these episodes was consistently shorter with the EE/GSD patch (p<0.01). There were no notable treatment differences in intracyclic bleeding. CONCLUSION(S): Bleeding pattern and cycle control achieved with the EE/GSD patch was similar to that of the EE/NGMN patch. IMPLICATIONS STATEMENT: The paper presents data on the bleeding pattern and cycle control parameters of an investigational transdermal contraceptive patch containing EE and GSD compared with an approved contraceptive patch containing EE and NGMN. This descriptive study found that bleeding patterns associated with the EE/GSD patch were similar to those of an EE/NGMN patch providing higher EE exposure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16021028
003      
CZ-PrNML
005      
20160725121344.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.contraception.2014.10.003 $2 doi
024    7_
$a 10.1016/j.contraception.2014.10.003 $2 doi
035    __
$a (PubMed)25453582
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gruber, D $u University Clinic, General Hospital Vienna, Department of Gynecological Endocrinology and Reproductive Medicine, Vienna, Austria.
245    12
$a A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study / $c D. Gruber, A. Skřivánek, M. Serrani, V. Lanius, M. Merz,
520    9_
$a OBJECTIVE(S): To investigate the bleeding pattern and cycle control parameters of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD) compared with a patch containing 0.6 mg EE and 6 mg norelgestromin (NGMN). STUDY DESIGN: In this phase III, open-label, randomized, parallel-group trial, healthy women aged 18-35 years (smokers aged 18-30 years) received either the EE/GSD patch (n=200) or the EE/NGMN patch (n=198). Treatment consisted of one patch per week for 3 weeks followed by a 7-day, patch-free interval for seven cycles. Bleeding control was assessed in two 90-day reference periods. RESULTS: In reference period 1, mean number of bleeding/spotting days was comparable across treatment groups (p>0.05). However, in reference period 2, there were fewer bleeding/spotting days in the EE/GSD patch group (15.7 versus 18.4; p<0.0001). Mean number of bleeding/spotting episodes was comparable across groups for both reference periods, but bleeding/spotting episodes were shorter for the EE/GSD patch than the EE/NGMN patch during reference period 1 (5.13 days versus 5.53 days, respectively; p<0.05) and reference period 2 (5.07 versus 5.66; p=0.0001). Both treatment groups showed a similar frequency of withdrawal bleeding episodes; however, across all seven cycles, the length of these episodes was consistently shorter with the EE/GSD patch (p<0.01). There were no notable treatment differences in intracyclic bleeding. CONCLUSION(S): Bleeding pattern and cycle control achieved with the EE/GSD patch was similar to that of the EE/NGMN patch. IMPLICATIONS STATEMENT: The paper presents data on the bleeding pattern and cycle control parameters of an investigational transdermal contraceptive patch containing EE and GSD compared with an approved contraceptive patch containing EE and NGMN. This descriptive study found that bleeding patterns associated with the EE/GSD patch were similar to those of an EE/NGMN patch providing higher EE exposure.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a amenorea $x chemicky indukované $x epidemiologie $7 D000568
650    _2
$a kontraceptiva ženská $x aplikace a dávkování $x škodlivé účinky $7 D003271
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a estrogeny $x aplikace a dávkování $x škodlivé účinky $7 D004967
650    _2
$a ethinylestradiol $x aplikace a dávkování $x škodlivé účinky $7 D004997
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mastodynie $x chemicky indukované $x epidemiologie $7 D059373
650    _2
$a silné menstruační krvácení $x chemicky indukované $x epidemiologie $7 D008595
650    _2
$a menstruační cyklus $x účinky léků $7 D008597
650    _2
$a metroragie $x chemicky indukované $x epidemiologie $7 D008796
650    _2
$a norgestrel $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D009644
650    _2
$a norpregneny $x aplikace a dávkování $x škodlivé účinky $7 D009652
650    _2
$a ukončení terapie pacientem $7 D010352
650    _2
$a progestiny $x aplikace a dávkování $x škodlivé účinky $7 D011372
650    12
$a transdermální náplast $x škodlivé účinky $7 D057968
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Rakousko $x epidemiologie $7 D001317
651    _2
$a Česká republika $x epidemiologie $7 D018153
651    _2
$a Nizozemsko $x epidemiologie $7 D009426
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Skřivánek, A $u G-CENTRUM, Olomouc, Czech Republic.
700    1_
$a Serrani, M $u Bayer Pharma AG, 13353 Berlin, Germany.
700    1_
$a Lanius, V $u Bayer Pharma AG, 13353 Berlin, Germany.
700    1_
$a Merz, M $u Bayer Pharma AG, 13353 Berlin, Germany. Electronic address: martin.merz@bayer.com.
773    0_
$w MED00001230 $t Contraception $x 1879-0518 $g Roč. 91, č. 2 (2015), s. 105-12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25453582 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725121602 $b ABA008
999    __
$a ok $b bmc $g 1155698 $s 945556
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 91 $c 2 $d 105-12 $e 20141013 $i 1879-0518 $m Contraception $n Contraception $x MED00001230
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace